Literature DB >> 11870835

Multislice first-pass cardiac perfusion MRI: validation in a model of myocardial infarction.

Frederick H Epstein1, James F London, Dana C Peters, Lino M Goncalves, Kwabena Agyeman, Joni Taylor, Robert S Balaban, Andrew E Arai.   

Abstract

The purpose of this study was to validate a first-pass MRI method for imaging myocardial perfusion with multislice coverage and relatively small analyzable regions of interest (ROIs). A fast gradient-echo (FGRE) sequence with an echo-train (ET) readout was used to achieve multislice coverage, and a high dose of a contrast agent (CA) was used to achieve a high signal-to-noise ratio (SNR). Dogs (N = 6) were studied 1 day after reperfused myocardial infarction, and fluorescent microspheres were used as a standard for perfusion. First-pass MRI correlated well vs. microsphere flow, achieving mean R values of 0.87 (range = 0.82-0.93), 0.71 (range = 0.46-0.85), and 0.72 (range = 0.49-0.95) for subendocardial ROIs, transmural ROIs, and the endocardial-epicardial ratio, respectively. Additionally, analysis of myocardial time-intensity curves (TICs) indicated that 15.8 +/- 6 sectors, corresponding to 260 microl of endocardium, can be analyzed (R(2) > 0.95).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870835     DOI: 10.1002/mrm.10085

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  20 in total

Review 1.  Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside.

Authors:  Pierre Croisille; Didier Revel; Maythem Saeed
Journal:  Eur Radiol       Date:  2006-04-22       Impact factor: 5.315

Review 2.  Myocardial perfusion imaging by magnetic resonance imaging.

Authors:  Katherine C Wu
Journal:  Curr Cardiol Rep       Date:  2003-01       Impact factor: 2.931

3.  Head to head comparison of quantitative versus visual analysis of contrast CMR in the setting of myocardial stunning after STEMI: implications on late systolic function and patient outcome.

Authors:  Oliver Husser; Vicente Bodi; Juan Sanchis; Julio Nunez; Luis Mainar; Pilar Merlos; Maria P Lopez-Lereu; Jose V Monmeneu; Fabian Chaustre; Eva Rumiz; Günter A J Riegger; Francisco J Chorro; Angel Llacer
Journal:  Int J Cardiovasc Imaging       Date:  2010-02-20       Impact factor: 2.357

Review 4.  Cardiovascular magnetic resonance: structure, function, perfusion, and viability.

Authors:  David C Isbell; Christopher M Kramer
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

Review 5.  Magnetic resonance cardiac perfusion imaging-a clinical perspective.

Authors:  Peter Hunold; Thomas Schlosser; Jörg Barkhausen
Journal:  Eur Radiol       Date:  2006-05-03       Impact factor: 5.315

Review 6.  Evaluation of ischemic heart disease.

Authors:  Dipan J Shah; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

7.  Role of first pass and delayed enhancement in assessment of segmental functional recovery after acute myocardial infarction.

Authors:  L Natale; C Napolitano; A Bernardini; A Meduri; R Marano; A Lombardo; F Crea; L Bonomo
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

8.  Comparison of myocardial perfusion estimates from dynamic contrast-enhanced magnetic resonance imaging with four quantitative analysis methods.

Authors:  Nathan A Pack; Edward V R DiBella
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

9.  Steady-state first-pass perfusion (SSFPP): a new approach to 3D first-pass myocardial perfusion imaging.

Authors:  Shivraman Giri; Hui Xue; Andrei Maiseyeu; Randall Kroeker; Sanjay Rajagopalan; Richard D White; Sven Zuehlsdorff; Subha V Raman; Orlando P Simonetti
Journal:  Magn Reson Med       Date:  2013-02-25       Impact factor: 4.668

Review 10.  Evaluation of the microcirculation: advances in cardiac magnetic resonance perfusion imaging.

Authors:  Amit R Patel; Frederick H Epstein; Christopher M Kramer
Journal:  J Nucl Cardiol       Date:  2008 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.